Peptide Library

In clinical trials

Immune & defense

Nangibotide

Evidence

Clinical trials

Class

TREM-1 inhibitor peptide

/

Nangibotide

KEY TAKEAWAY

Nangibotide is a 12-amino-acid peptide that blocks TREM-1, a receptor that amplifies inflammation during infection. Inotrem is developing it for septic shock. Nangibotide is not FDA-approved and has been tested in phase 2 and phase 3 trials.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

TREM-1 inhibitor peptide

Being studied for

Studied in septic shock

Key fact

Nangibotide is not FDA-approved and has been tested in phase 2 and phase 3 trials.

Route

Intravenous infusion in trials

Evidence strength

Clinical trials

What it is

What it is

Nangibotide is a 12-amino-acid peptide that blocks TREM-1, a receptor that amplifies inflammation during infection. Inotrem is developing it for septic shock.

How it works

How it works

By limiting TREM-1 signaling, it aims to calm the overactive immune response that damages organs in sepsis.

Regulatory status

Regulatory status

Nangibotide is not FDA-approved and has been tested in phase 2 and phase 3 trials.

What it is used for

What it is used for

Studied in septic shock.

Side effects and risks

Side effects and risks

Trials in critically ill patients reported adverse events at rates similar to placebo, but data are still being evaluated.

Citations

Citations

Nangibotide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo